Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mount Sinai, discusses how neurologic symptoms in individuals with HIV can present in various places in the body while also possibly pointing to a neurologic condition.
Some neurologic symptoms in patients with HIV can be more obvious than others, says Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mount Sinai.
Transcript
What are some symptoms you look for in patients with HIV who you may suspect have a neurological complication of their HIV?
That can be really broad, and some of the symptoms, I think, are more overt than others. So, for example, in patients who have advanced immunosuppression and AIDS and we're worried about an infection in the brain, some of the symptoms might be things like headache or confusion [or] seizures. If it's an infection, you could have fever and other kinds of systemic signs of infection.
If it is a patient who is not particularly immunosuppressed, and has been doing well, often those neurologic complications are similar to somebody who didn't have HIV. In that case, you’re just basically starting with the symptoms that the patient complains of. Some of the things that I see a lot of are peripheral neuropathies. Those patients will sometimes complain of pain or numbness or tingling in the bottoms of their feet or coming up their legs. That can be a common symptom.
One of the other disorders that we see a lot of are HIV-associated neurocognitive disorders, which is abbreviated HAND, and those patients may report difficulty with different cognitive processes. So, maybe they're having trouble focusing like they used to, or handling their finances or their appointments or managing in their day-to-day life.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More